Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Transparency is important to us. Find important information about Kuros Biosciences here – from our corporate documents to our current share price.
Here are our latest press releases.
For archived news items, please go to our Resources center. To subscribe to receive our press releases, please click here.
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
Adhoc Press Release
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOs sales
Date | Event |
---|---|
Oct 10, 2024 | Trading Update Q3 2024 |
Kuros Biosciences is fully committed to good corporate governance and adherence to high ethical standards. Our principles and rules on corporate governance and ethical conduct are articulated in the Articles of Association, the Internal Regulations, the charters of the committees of our board of directors, and our code of conduct.
For more information regarding analyst reports, please contact:
Laura Pfeifer-Rossi
Octavian AG
sales@octavian.ch
Tel: +41 44 520 1588
Want to receive our press releases?